Leading the Way in Healthcare Innovation Across the Medication Journey SAN ANTONIO, March 3, 2025 /PRNewswire/ -- DrFirst, a leading…
One of Ohio's largest integrated health systems deploys the 1Clearsense Platform to create a longitudinal EHR, enabling comprehensive access to…
Clearlake to Acquire ModMed from Warburg Pincus BOCA RATON, Fla., March 3, 2025 /PRNewswire/ -- ModMed® (the "Company"), a pioneer in specialty-specific healthcare…
New functionality within Counterpart Assistant uses Google Cloud’s Vertex AI Search to give clinicians comprehensive insights across multiple sources of…
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement…
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on…
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS…
If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab…
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney…
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product…